Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IMS global Rx sales

Executive Summary

North American pharmaceutical sales growth was outpaced by all other markets in 2005, IMS Health reports. For the year, sales in North America grew 5.2% (to $265.7 bil.), compared to 7.1% growth in Europe (to $169.5 bil.), 6.8% growth in Japan (to $60.3 bil.), 18.5% growth in Latin America (to $24 bil.) and 11% growth in Africa and non-Japan Asia Pacific (to $46.4 bil.). Biologics as a sector grew 17.1% in 2005, bringing their total sales to $52.7 bil. Leading products in terms of sales were Pfizer's Lipitor (6.4% growth to $12.9 bil.), Sanofi-Aventis/Bristol-Myers Squibb's Plavix (16% growth to $5.9 bil.) and AstraZeneca's Nexium (16.7% growth to $5.7 bil.)...

You may also be interested in...

QUOTED. 18 September 2020. Ed Israelski.

The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.

US Bill Urges Automatic Insulin Interchangeability

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts